3 million in the third quarter of 2007 as compared to the prior year period due to an asset impairment charge incurred on the company's Retavase
product in the fourth quarter of 2006.
is a recombinant mutein of alteplase, but only recently have preliminary studies on its use in catheter-directed thrombolysis been reported (3).
Crystaal, Biovail's Canadian sales and marketing division, continued to gain market share through an expanded portfolio of products which, along with Tiazac(R), includes Retavase
, Brexidol, Celexa and Cardiac STATus.
to advise it on the sale of the rights to Cardene, Retavase
, IV Busulfex and ularitide, and related assets, in one or more transactions.
5 million charge related to analyzing and improving the Retavase
manufacturing process with a contract manufacturer.
has a license from Centocor to use the trademark Retavase
, which is a registered U.
Unfortunately, instead of channeling this royalty stream into earnings generation and expeditious product development, you made what we consider to be an ill- conceived purchase of ESP Pharma for $500M to gain access to products Cardene IV, Retavase
and IV Busulfex(R) subsequent to acquiring the rights to these products in March 2005.
9 million in other-acquisition related charges related to ESP Pharma operations prior to the company's acquisition of the business and product sales returns of Retavase
from sales made prior to the acquisition of the rights to Retavase
in March 2005; a $5.
Net product sales in the second quarter of 2006, which were comprised solely of Cardene IV, Retavase
and IV Busulfex, were $39.
Factors that may cause differences between current expectations and actual results include, but are not limited to, the following: The continued successful integration of ESP Pharma and Retavase
as part of PDL, including the retention of the sales force; changes in our development plans as we and our collaborators consider development plans and alternatives; factors affecting the clinical timeline such as enrollment rates and availability of clinical materials; changes in the market due to alternative treatments or other actions by competitors; and variability in expenses particularly on a quarterly basis, due, in principal part, to total headcount of the organization and the timing of expenses.
Weisman noted that many of the EKR management team and several of its investors had previously collaborated on Cardene and Retavase